A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
| 대상 질환 | Triple Negative Breast Neoplasms |
|---|---|
| 임상 단계 | 1/2상 |
| 스폰서 | AstraZeneca |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 243 명 |
| 중재(약물) | Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan |
| 시작일 | 2018년 12월 21일 |
| 완료일 | 2024년 11월 29일 |
| 결과 공개일 | 2026년 2월 2일 |
요약
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
Dose Limiting Toxicity (DLT) Events
| Arm 2 | 0 Participants |
|---|---|
| Arm 5 | 0 Participants |
| Arm 6 | 0 Participants |
| Arm 7 | 0 Participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Vitamin D and Physical Activity on Bone Health — University of Rochester
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in T — National Cancer Institute (NCI)
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor — National Cancer Institute (NCI)
- Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced — National Cancer Institute (NCI)
- Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Adm — University of Colorado, Denver
- Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer — National Cancer Institute (NCI)